Lexeo Therapeutics, Inc. Contracts & Agreements
34 Contracts & Agreements
- Business Finance (7 contracts)
- Business Operations (2)
- Human Resources (11)
- Intellectual Property (11)
- Uncategorized (3)
- Third License Agreement, dated April 21, 2024, by and between Cornell University and the Company (Filed With SEC on August 12, 2024)
- Employment Agreement, dated April 10, 2024, by and between the Company and Jose Manuel Otero (Filed With SEC on August 12, 2024)
- 2021 Equity Incentive Plan, as amended from time to time and Form of Stock Option Agreement, Early Exercise Notice and Restricted Stock Purchase Agreement, and Exercise Notice (Filed With SEC on August 12, 2024)
- Amendment No. 3, dated February 11, 2024, to the First License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University (as amended by... (Filed With SEC on April 9, 2024)
- Employment Agreement, dated February 2, 2024, by and between the Company and Sandi See Tai, M.D (Filed With SEC on April 9, 2024)
- Employment Agreement, dated February 3, 2024, by and between the Company and Eric Adler, M.D (Filed With SEC on April 9, 2024)
- Form of Registration Rights Agreement, dated March 11, 2024 (Filed With SEC on March 11, 2024)
- Description of Securities of the Registrant (Filed With SEC on March 11, 2024)
- Form of Common Stock Purchase Agreement, dated March 11, 2024 (Filed With SEC on March 11, 2024)
- 2023 Employee Stock Purchase Plan (Filed With SEC on October 30, 2023)
- 2023 Equity Incentive Plan and Forms of Option Grant Notice and Agreement, Exercise Notice and Restricted Stock Unit Award Notice (Filed With SEC on October 30, 2023)
- Form of Common Stock Certificate of the Registrant (Filed With SEC on October 30, 2023)
- Form of Underwriting Agreement (Filed With SEC on October 30, 2023)
- Amendment No. 1, dated July 4, 2022, to the First License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University and Amendment No. 2, dated... (Filed With SEC on September 29, 2023)
- License Agreement, dated January 19, 2021, between Adverum Biotechnologies, Inc. and LEXEO Therapeutics, Inc., as amended by the First Amendment, dated February 28, 2022 (Filed With SEC on September 29, 2023)
- Research Collaboration Agreement, dated February 3, 2021, by and between Cornell University and LEXEO Therapeutics, Inc. as amended by Amendment No. 1, dated February 1, 2022 (Filed With SEC on September 29, 2023)
- Amendment No. 2, dated September 28, 2022, to the First License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University (as amended by... (Filed With SEC on September 29, 2023)
- License Agreement, dated October 4, 2021, by and between LEXEO Therapeutics, Inc. and the Regents of the University of California (Filed With SEC on September 29, 2023)
- 2021 Equity Incentive Plan, as amended from time to time and Form of Stock Option Agreement, Early Exercise Notice and Restricted Stock Purchase Agreement, and Exercise Notice (Filed With SEC on September 29, 2023)
- Form of Indemnification Agreement with Executive Officers and Directors (Filed With SEC on September 29, 2023)
- Amended and Restated Employment Agreement, dated September 28, 2023, by and between the Company and R. Nolan Townsend (Filed With SEC on September 29, 2023)
- Amended and Restated Employment Agreement, dated September 28, 2023, by and between the Company and Jenny R. Robertson (Filed With SEC on September 29, 2023)
- Amended and Restated Employment Agreement, dated September 28, 2023, by and between the Company and Paul McCormac (Filed With SEC on September 29, 2023)
- Consulting Agreement, dated October 9, 2020, between LEXEO Therapeutics, LLC and Ronald G. Crystal, M.D (Filed With SEC on September 29, 2023)
- Consulting Agreement, dated July 16, 2021, between LEXEO Therapeutics, LLC and Eric Adler, M.D (Filed With SEC on September 29, 2023)
- Stock Purchase Agreement, dated July 16, 2021, by and among LEXEO Therapeutics, Inc., Stelios Therapeutics, Inc., The Cystinosis Research Foundation, Eric Adler, M.D., Farah... (Filed With SEC on September 29, 2023)
- Amended and Restated Investors Rights Agreement, by and among the Registrant and certain of its stockholders, dated August 10, 2021 (Filed With SEC on September 29, 2023)
- License Agreement, dated April 23, 2020, by and between Stelios Therapeutics, Inc. (as successor-in-interest to ARVC Therapeutics, Inc.) and the Regents of the University of... (Filed With SEC on September 29, 2023)
- License Agreement, dated August 6, 2020, by and between Stelios Therapeutics, Inc. and the Regents of the University of California (Filed With SEC on September 29, 2023)
- ARVC Research Agreement, dated December 3, 2021, between LEXEO Therapeutics, Inc. and the Regents of the University of California, as amended by Amendment No. 1, dated April 5,... (Filed With SEC on September 29, 2023)
- TNNI3 Research Agreement, dated December 3, 2021, between LEXEO Therapeutics, Inc. and the Regents of the University of California, as amended by Amendment No. 1, dated April 19,... (Filed With SEC on September 29, 2023)
- First License Agreement, dated May 28, 2020, between LEXEO Therapeutics, LLC and Cornell University (Filed With SEC on September 29, 2023)
- Second License Agreement, dated May 28, 2020, between LEXEO Therapeutics, LLC and Cornell University (Filed With SEC on September 29, 2023)
- Amendment No. 1, dated January 13, 2022, to the Second License Agreement, dated May 28, 2020, by and between LEXEO Therapeutics, Inc. and Cornell University (Filed With SEC on September 29, 2023)
